The natural psychedelics company responsible for creating the first standardized ayahuasca capsule, Filament Health Corp. FLHLF, shared its financial results and operational highlights for the period ended December 31, 2022.
Numbers show:
-
Total cash of $2.08 (CA$2.8) million as of Dec. 31, 2022, as compared to $3.4 million by Dec. 31, 2021.
-
Cash starting point of 2022 was $4.6 million, while $652.937 in 2021.
-
R&D expenses nearly doubled, from $354.258 in 2021 to $623.744 in 2022.
-
2022 saw no expenses in clinical trials compared to the $679.113 spent in 2021, yet a newly acquired licensing revenue of $270.932.
-
Yearly net and comprehensive loss of $12.1 million compared to $6.8 million the prior year, including total expenses of $4.4 million vs. $6.9 million respectively.
-
2022 saw a 2021-inexistent impairment of goodwill for a total $7.9 million.
During the fourth and last quarter of 2022, the company’s milestones included the successful subject dosing in a Canadian psilocybin trial run by ATMA Journey Centers; an academic supply agreement with the Center for Addictions and Mental Health (CAMH); two new patent issuances from the USPTO; and a global licensing agreement with Psyence Group to provide PEX010 (25mg) for clinical trials in palliative care.
See also: Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier
Moving forward into 2023, Filament created joint venture Magdalena Biosciences Inc. with Jaguar Health Inc. JAGX; has PEX010 participating at two investigator-initiated trials, one for patients with Alcohol Use Disorder (AUD) at Psychiatric Centre Copenhagen and another at the UC-SF’s Translational Psychedelic Research Program for patients with Methamphetamine Use Disorder (MAUD); and finally, inked a second supply agreement with CAMH, this time for PEX010 tested for mild cognitive impairment.
Benzinga’s Psychedelics Capital Conference is almost here!
April 13th at the Fontainebleau Hotel in Miami Beach will be THE place to set up deals, raise money, meet investors and key partners and learn from the industry’s greatest.
Get your tickets now!
Photo: Benzinga edit with photo by Raimundo79 and Blue Planet Studio on Shutterstock.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!